Comparing Bolus and Continuous Infusion Chemotherapy for Small Cell Lung Cancer
Author Information
Author(s): H. Anderson, P. Hopwood, J. Prendiville, J.A. Radford, N. Thatcher, L. Ashcroft
Primary Institution: Christie Hospital, Manchester, UK
Hypothesis
Is continuous infusion chemotherapy as effective as bolus therapy for small cell lung cancer?
Conclusion
Continuous infusion chemotherapy is as effective as bolus therapy and is better tolerated by patients.
Supporting Evidence
- The overall response rate was 64% for bolus therapy and 69% for continuous infusion therapy.
- The median survival was 25 weeks for bolus therapy and 30 weeks for continuous infusion therapy.
- Patients on continuous infusion experienced less haematological toxicity.
- Quality of life assessments showed reduced anxiety and depression for both treatment groups.
Takeaway
This study looked at two ways to give chemotherapy to patients with lung cancer. It found that using a pump to give the medicine slowly over time works just as well as giving it all at once.
Methodology
Patients were randomly assigned to receive either bolus or continuous infusion chemotherapy for six weeks, and their responses and side effects were monitored.
Potential Biases
There were protocol violations and potential biases in patient selection.
Limitations
The study had a small sample size and only included patients who were not eligible for intensive chemotherapy.
Participant Demographics
Patients were previously untreated adults aged 18-75 with small cell lung cancer.
Statistical Information
P-Value
P = 0.45
Confidence Interval
95% CI 7-22% for bolus therapy and 95% CI 11-30% for continuous infusion therapy
Want to read the original?
Access the complete publication on the publisher's website